

ACT Genomics completes latest round of equity financing

26 September 2018 | News

The company's mission is to provide every cancer patient personalized genomic information-based treatment plans through the cutting-edge Next Generation Sequencing (NGS) platform.



ACT Genomics Holdings Company Limited has recently announced the completion of the latest round of equity financing from a group of international investors co-led by CLSA Capital Partners.

Founded in 2014, ACTG is Asia's leading DNA sequencing-based cancer solution providers and transforms science into actionable solutions empowering clinicians and patients with evidence-based information to fight cancer. The company's mission is to provide every cancer patient personalized genomic information-based treatment plans through the cutting-edge Next Generation Sequencing (NGS) platform, Asian genome database, leading professional bioinformatics and biomedical team in Asia, medical report, and integrated services.

Currently, the company has operations in Taiwan, Hong Kong, Singapore and Japan. ACTG has also established a joint venture with Canon Medical System Corporation in Japan to operate cancer genomic profiling service and sequencing data analysis covering Japan.